CSF1 and tenosynovial giant cell tumor, diffuse type: Studies of TAM depletion strategies with limited efficacy in most cancers, including CSF1/CSF1R inhibitors (e.g., PLX3397), showed limited monotherapy efficacy, except in CSF1R-driven tumors, like diffuse-type giant cell tumors [52].